Supernus Pharmaceuticals (SUPN) Stock Statistics & Valuation Metrics

Supernus Pharmaceuticals has a market cap or net worth of $1.72B. The enterprise value is $1.62B.

Supernus Pharmaceuticals has 55,814,495 shares outstanding. The number of shares has decreased by -2.65% in one year.

Supernus Pharmaceuticals’s return on equity (ROE) is 0.07 and return on invested capital (ROIC) is 5.69%.

The current PE Ratio of Supernus Pharmaceuticals is 26.97. Supernus Pharmaceuticals’s PEG ratio is <0.01.

In the last 12 months, Supernus Pharmaceuticals had revenue of 661.82M and earned 73.86M in profits. Earnings per share was 1.34.

In the last 12 months, operating cash flow was 171.95M and capital expenditures -725.00K, giving a free cash flow of 171.23M billion.

Supernus Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Supernus Pharmaceuticals upcoming earnings date is May 6, 2025, TBA Not Confirmed.

Supernus Pharmaceuticals as a current ratio of 2.35, with Debt / Equity ratio of 3.31%

In the past 12 months, Supernus Pharmaceuticals has paid 24.00M in taxes.

Supernus Pharmaceuticals EV to EBITDA ratio is 10.98, with an EV/FCF ratio of 11.43.

Supernus Pharmaceuticals has $453.61M in cash and marketable securities with $75.00M in debt, giving a net cash position of -$419.34M billion.

Gross margin is 78.93%, with operating margin of 12.34%, and net profit margin of 11.16%.

The average price target for Supernus Pharmaceuticals is $38.80, which is 11.43% higher than the current price. The consensus rating is Moderate Buy